CSIMarket
 
Gracell Biotechnologies Inc   (GRCL)
Other Ticker:  
 
 
Price: $10.2500 $0.01 0.049%
Day's High: $10.28 Week Perf: -0.19 %
Day's Low: $ 10.17 30 Day Perf: 2.3 %
Volume (M): 6,417 52 Wk High: $ 10.44
Volume (M$): $ 65,775 52 Wk Avg: $4.57
Open: $10.26 52 Wk Low: $1.40



 Market Capitalization (Millions $) 3,468
 Shares Outstanding (Millions) 338
 Employees 365
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -88
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 7

Gracell Biotechnologies Inc
Gracell Biotechnologies Inc. is a clinical-stage biotechnology company focused on developing cell therapies for various types of cancers. The company was founded in 2017 and is headquartered in Suzhou, China, with additional facilities in the United States.

Gracell's approach to cancer treatment involves using a patient's own immune cells to fight the disease. They do this by taking T-cells, a type of white blood cell, from the patient and genetically modifying them using a proprietary platform known as FasTCAR. This process enables the T-cells to recognize and attack cancer cells more effectively while avoiding harm to healthy cells.

The company's flagship product, GC007g, is a potentially curative therapy for relapsed or refractory B-cell malignancies, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The treatment involves a single infusion of the modified T-cells, which have demonstrated high response rates and extended remission periods in clinical trials. Gracell is also developing a pipeline of additional cell therapies for various solid tumors and other blood cancers.

Gracell has established partnerships with several leading cancer research institutions and biopharmaceutical companies worldwide. These partnerships leverage Gracell's expertise in cell therapy development and their proprietary technology to advance the field of cancer treatment.

In addition to their scientific research, Gracell is committed to making their therapies accessible to patients worldwide. The company has established a global supply chain network to ensure their products can be manufactured and distributed efficiently and cost-effectively, while maintaining the highest standards of quality and safety.

Overall, Gracell Biotechnologies Inc. is a cutting-edge biotech company with a significant focus on innovation in cancer treatment. With a robust pipeline of potentially revolutionary cell therapies and a commitment to patient accessibility, Gracell is well-positioned to continue making significant advances in the fight against cancer in the coming years.


   Company Address: Building 12, Block B, Phase II Suzhou 215123
   Company Phone Number: 6262-6701   Stock Exchange / Ticker: NASDAQ GRCL
   GRCL is expected to report next financial results on April 24, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Merger and Acquisition

Gracell Biotechnologies Acquisition Completed: A Revolutionary Consolidation in Cell Therapies

Published Thu, Feb 22 2024 1:45 PM UTC



SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 - Gracell Biotechnologies Inc. (Gracell or the Company, Nasdaq: GRCL) announced the successful completion of its acquisition by AstraZeneca. This historic merger marks a significant achievement for both companies, bringing together Gracell's innovative cell therapy solutions and AstraZeneca's global pre...

Stock Market Announcement

Gracell Biotechnologies Announces Shareholder Approval for Merger with AstraZeneca Treasury, Expanding Global Impact in Cell Therapy Development.

Published Tue, Feb 20 2024 12:45 PM UTC

Gracell Biotechnologies, a global clinical-stage biopharmaceutical company, has announced that its shareholders have voted in favor of a proposed merger with AstraZeneca Treasury and Grey Wolf Merger Sub. This merger, subject to regulatory approval, will make Gracell a wholly-owned subsidiary of AstraZeneca. The agreement aims to further advance the development of innovative...

Product Service News

Gracell Biotechnologies Escalates Treatment for Refractory Systemic Lupus Erythematosus with NMPA and FDA Clearance for Phase 1/2 Clinical Trial

Published Thu, Dec 21 2023 12:00 PM UTC

Chinese company Gracell Biotechnologies is poised to make significant strides in the treatment of refractory Systemic Lupus Erythematosus (rSLE). The biotech giant has announced that it has received clearance for IND (Investigational New Drug) application for its Phase 1/2 Clinical Trial of FasTCAR-T GC012F from both the China National Medical Products Administration (NMPA) ...

Clinical Study

Game-Changing Innovations: Nitric Oxide Delivery System and Revenue Surge Propel Third Pole Therapeutics and Gracell Biotechnologies Inc Forward

Published Mon, Dec 11 2023 9:05 PM UTC


:
The healthcare industry is constantly evolving, and innovative technologies are paving the way for groundbreaking treatments. In this article, we will discuss the recent developments regarding Third Pole Therapeutics' Feasibility Study with the eNOfit Portable Inhaled Nitric Oxide Delivery System and provide an assessment of its impact on the company. Additionally...

Clinical Study

Gracell Biotechnologies Revolutionizes Treatment for Refractory Systemic Lupus Erythematosus with Breakthrough CAR-T Therapy

Published Mon, Nov 27 2023 1:01 PM UTC



Gracell Biotechnologies, a leading biotechnology company specializing in innovative cellular immunotherapies, recently received FDA clearance for its investigational new drug (IND) application for Phase 1/2 clinical trials of FasTCAR-T GC012F. This groundbreaking therapy aims to address the unmet medical needs of patients suffering from refractory systemic lupus er...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com